By Dr Nikola Mitrev

Journal articles

Kariyawasam V; Davis T; Ghali M; Tejcek D; R O'Neil T; Verley E; Griffiths M; Campos M; Bonney I; Bulmer AC; Ramaswamy Y; Mitrev N; Corte C; Witting PK; Chami B, 2026, 'Myeloperoxidase Luminol Reaction – A Novel Faecal Assay for Predicting Colonoscopy Findings in Patients with Ulcerative Colitis: A Pilot Cross-Sectional Clinical Study', Advanced Healthcare Materials, 15, http://dx.doi.org/10.1002/adhm.202501825

Maguire B; Mitrev N; Baraty B; Au M; Sorensen K; Kariyawasam V, 2026, 'Exploring the Perceptions and Practices of Exclusive Enteral Nutrition Among Adult Patients With Inflammatory Bowel Disease, Gastroenterologists and Dietitians in Australia', JCC Plus, 1, http://dx.doi.org/10.1002/jcc5.70021

An YK; Lindsay N; Allan N; Khoo E; Fernandes R; Gilmore R; Amiss A; Pham H; Ooi SY; Thin L; Lightowler D; Connor SJ; Williams A; De Cruz P; Li Wai Suen CFD; Kariyawasam V; Mitrev N; Ghaly S; Andrews JM; Christensen B; Sparrow MP; White LS; Bryant R; Ding NS; Leong RW; Van Langenberg DR; Seltenreich H; Subramaniam K; Radford-Smith G; Begun J, 2025, 'Australian Real-World Effectiveness and Safety of Ustekinumab for the Treatment of Crohn's Disease: Results of the AURORA Study, Including the ANZIBD Consortium', Jgh Open, 9, http://dx.doi.org/10.1002/jgh3.70322

Karimi N; Moore AR; Jones A; Lukin A; Pipicella JL; Williams AJ; Ng W; Kanazaki R; Kariyawasam V; Mitrev N; Pandya K; Andrews JM; Connor SJ, 2025, 'On being on the same page: Predictors of gastroenterologist-patient misalignment in inflammatory bowel disease', Patient Education and Counseling, 130, http://dx.doi.org/10.1016/j.pec.2024.108487

Mitrev N; Kariyawasam V, 2024, 'Treatment endpoints in ulcerative colitis: Does one size fit all?', World Journal of Gastrointestinal Pharmacology and Therapeutics, 15, pp. 91591, http://dx.doi.org/10.4292/wjgpt.v15.i2.91591

Huang D; Rennie M; Krasovec A; Nagubandi S; Liu S; Ge E; Khehra B; Au M; Sivagnanam S; Kwan V; Rogge C; Mitrev N; Kariyawasam V, 2024, 'Impact of cytomegalovirus on outcomes in acute severe ulcerative colitis: a retrospective observational study', Therapeutic Advances in Chronic Disease, 15, http://dx.doi.org/10.1177/20406223241233203

Karimi N; Lukin A; Moore AR; Pipicella JL; Kanazaki R; Williams AJ; Ng W; Kariyawasam V; Mitrev N; Pandya K; Connor SJ, 2023, 'Adolescents and young adults communicating with gastroenterologists: Variation in inflammatory bowel disease clinical communication', International Journal of Adolescent Medicine and Health, 35, pp. 347 - 361, http://dx.doi.org/10.1515/ijamh-2023-0078

Au M; Low P; Rennie M; Mohseni M; Song Y; Kim N; Baraty B; Mitrev N; He E; Ho V; Leong R; Kariyawasam V, 2023, 'Determining efficacy of dynamic multimedia bowel preparation instructions versus standard instructions on adenoma detection and patient reported measures (DIGICLEAN trial): A study protocol for a multicentre, colonoscopist-blinded, randomised controlled trial', BMJ Open, 13, http://dx.doi.org/10.1136/bmjopen-2023-073843

An YK; Lindsay N; Allan N; Khoo E; Fernandes R; Amiss A; Pham H; Wong KF; Ooi SY; Thin L; Lightowler D; Connor SJ; Williams AJ; De Cruz P; Li Wai Suen C; Kariyawasam V; Mitrev N; Ghaly S; Andrews JM; Christensen B; Sparrow MP; White LS; Bryant RV; Ding N; Leong R; Van Langenberg D; Seltenreich H; Subramaniam K; Radford-Smith G; Begun J, 2023, 'P663 Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn’s disease patients: results from the AURORA Study including ANZIBDC Cohort', Journal of Crohn's and Colitis, 17, pp. i793 - i794, http://dx.doi.org/10.1093/ecco-jcc/jjac190.0793

Sheiban A; Maguire B; Ghali M; Premachandra N; Niazi K; Baraty B; Mitrev N; Kariyawasam V, 2023, 'S1183 Exclusive Enteral Nutrition Among Adult Patients With Active Crohn’s Disease: A Single Center Experience', The American Journal of Gastroenterology, 118, pp. s905 - s905, http://dx.doi.org/10.14309/01.ajg.0000954372.89674.f4

Au M; Mitrev N; Leong RW; Kariyawasam V, 2022, 'Dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn’s disease: A case report and review of literature', World Journal of Clinical Cases, 10, pp. 2569 - 2576, http://dx.doi.org/10.12998/wjcc.v10.i8.2569

Kariyawasam VC; Mourad FH; Mitrev N; Paramsothy S; Selinger CP; Katelaris PH; Jones B; McDonald C; Barr G; Chapman G; Cowlishaw J; Andrews J; Leong RW, 2021, 'Early thiopurine maintenance is associated with reduced proximal disease progression and colectomy rate in ulcerative colitis', European Journal of Gastroenterology and Hepatology, 33, pp. 1524 - 1532, http://dx.doi.org/10.1097/MEG.0000000000002101

Mitrev N; Huang H; Hannah B; Kariyawasam VC, 2021, 'Review of exclusive enteral therapy in adult Crohn's disease', BMJ Open Gastroenterology, 8, http://dx.doi.org/10.1136/bmjgast-2021-000745

Cheema M; Mitrev N; Hall L; Tiongson M; Ahlenstiel G; Kariyawasam V, 2021, 'Depression, anxiety and stress among patients with inflammatory bowel disease during the COVID-19 pandemic: Australian national survey', BMJ Open Gastroenterology, 8, pp. e000581, http://dx.doi.org/10.1136/bmjgast-2020-000581

Mitrev N; Kariyawasam V, 2020, 'Review of therapeutic drug monitoring of infliximab in spondyloarthritis—Catching up with management concepts from other inflammatory conditions', British Journal of Clinical Pharmacology, 86, pp. 194 - 195, http://dx.doi.org/10.1111/bcp.14129

Mitrev N; Vande Casteele N; Seow CH; Andrews JM; Connor SJ; Moore GT; Barclay M; Begun J; Bryant R; Chan W; Corte C; Ghaly S; Lemberg DA; Kariyawasam V; Lewindon P; Martin J; Mountifield R; Radford-Smith G; Slobodian P; Sparrow M; Toong C; van Langenberg D; Ward MG; Leong RW, 2017, 'Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases', Alimentary Pharmacology and Therapeutics, 46, pp. 1037 - 1053, http://dx.doi.org/10.1111/apt.14368

Mitrev N; Kariyawasam V; Leong RW, 2017, 'Editorial: infliximab trough cut-off for perianal Crohn's disease – another piece of the therapeutic drug monitoring-guided infliximab dosing puzzle', Alimentary Pharmacology and Therapeutics, 45, pp. 1279 - 1280, http://dx.doi.org/10.1111/apt.14020

Mitrev N; Leong RW, 2017, 'Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease', Expert Opinion on Drug Safety, 16, pp. 303 - 317, http://dx.doi.org/10.1080/14740338.2017.1269169

Back to profile page